nodes	percent_of_prediction	percent_of_DWPC	metapath
Pomalidomide—PTGS2—amyotrophic lateral sclerosis	0.476	1	CbGaD
Pomalidomide—CYP1A2—Riluzole—amyotrophic lateral sclerosis	0.292	1	CbGbCtD
Pomalidomide—White blood cell count decreased—Riluzole—amyotrophic lateral sclerosis	0.00677	0.0478	CcSEcCtD
Pomalidomide—Lymphopenia—Riluzole—amyotrophic lateral sclerosis	0.00659	0.0464	CcSEcCtD
Pomalidomide—Platelet count decreased—Riluzole—amyotrophic lateral sclerosis	0.00567	0.04	CcSEcCtD
Pomalidomide—Embolism—Riluzole—amyotrophic lateral sclerosis	0.00525	0.037	CcSEcCtD
Pomalidomide—Hypercalcaemia—Riluzole—amyotrophic lateral sclerosis	0.00485	0.0342	CcSEcCtD
Pomalidomide—Interstitial lung disease—Riluzole—amyotrophic lateral sclerosis	0.00476	0.0336	CcSEcCtD
Pomalidomide—Pulmonary embolism—Riluzole—amyotrophic lateral sclerosis	0.00337	0.0238	CcSEcCtD
Pomalidomide—Depressed level of consciousness—Riluzole—amyotrophic lateral sclerosis	0.00325	0.023	CcSEcCtD
Pomalidomide—Sepsis—Riluzole—amyotrophic lateral sclerosis	0.00292	0.0206	CcSEcCtD
Pomalidomide—Cardiac failure congestive—Riluzole—amyotrophic lateral sclerosis	0.0027	0.019	CcSEcCtD
Pomalidomide—Atrial fibrillation—Riluzole—amyotrophic lateral sclerosis	0.00258	0.0182	CcSEcCtD
Pomalidomide—Hyponatraemia—Riluzole—amyotrophic lateral sclerosis	0.00246	0.0173	CcSEcCtD
Pomalidomide—Urinary retention—Riluzole—amyotrophic lateral sclerosis	0.00233	0.0164	CcSEcCtD
Pomalidomide—Lenalidomide—PTGS2—amyotrophic lateral sclerosis	0.00231	0.625	CrCbGaD
Pomalidomide—Dehydration—Riluzole—amyotrophic lateral sclerosis	0.00228	0.016	CcSEcCtD
Pomalidomide—Hypokalaemia—Riluzole—amyotrophic lateral sclerosis	0.00223	0.0157	CcSEcCtD
Pomalidomide—Breast disorder—Riluzole—amyotrophic lateral sclerosis	0.00221	0.0156	CcSEcCtD
Pomalidomide—Muscular weakness—Riluzole—amyotrophic lateral sclerosis	0.00216	0.0152	CcSEcCtD
Pomalidomide—Alanine aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00216	0.0152	CcSEcCtD
Pomalidomide—Bronchitis—Riluzole—amyotrophic lateral sclerosis	0.00203	0.0143	CcSEcCtD
Pomalidomide—Pancytopenia—Riluzole—amyotrophic lateral sclerosis	0.00201	0.0142	CcSEcCtD
Pomalidomide—Neutropenia—Riluzole—amyotrophic lateral sclerosis	0.00198	0.0139	CcSEcCtD
Pomalidomide—Weight increased—Riluzole—amyotrophic lateral sclerosis	0.00192	0.0136	CcSEcCtD
Pomalidomide—Weight decreased—Riluzole—amyotrophic lateral sclerosis	0.00191	0.0135	CcSEcCtD
Pomalidomide—Pneumonia—Riluzole—amyotrophic lateral sclerosis	0.0019	0.0134	CcSEcCtD
Pomalidomide—Infestation NOS—Riluzole—amyotrophic lateral sclerosis	0.00189	0.0133	CcSEcCtD
Pomalidomide—Infestation—Riluzole—amyotrophic lateral sclerosis	0.00189	0.0133	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Riluzole—amyotrophic lateral sclerosis	0.00185	0.013	CcSEcCtD
Pomalidomide—Urinary tract infection—Riluzole—amyotrophic lateral sclerosis	0.00183	0.0129	CcSEcCtD
Pomalidomide—Hepatobiliary disease—Riluzole—amyotrophic lateral sclerosis	0.00178	0.0126	CcSEcCtD
Pomalidomide—Epistaxis—Riluzole—amyotrophic lateral sclerosis	0.00178	0.0125	CcSEcCtD
Pomalidomide—Urinary tract disorder—Riluzole—amyotrophic lateral sclerosis	0.00167	0.0118	CcSEcCtD
Pomalidomide—Oedema peripheral—Riluzole—amyotrophic lateral sclerosis	0.00167	0.0118	CcSEcCtD
Pomalidomide—Connective tissue disorder—Riluzole—amyotrophic lateral sclerosis	0.00166	0.0117	CcSEcCtD
Pomalidomide—Urethral disorder—Riluzole—amyotrophic lateral sclerosis	0.00166	0.0117	CcSEcCtD
Pomalidomide—Cardiac disorder—Riluzole—amyotrophic lateral sclerosis	0.00157	0.0111	CcSEcCtD
Pomalidomide—Angiopathy—Riluzole—amyotrophic lateral sclerosis	0.00154	0.0108	CcSEcCtD
Pomalidomide—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00153	0.0108	CcSEcCtD
Pomalidomide—Chills—Riluzole—amyotrophic lateral sclerosis	0.00152	0.0107	CcSEcCtD
Pomalidomide—Mental disorder—Riluzole—amyotrophic lateral sclerosis	0.00148	0.0105	CcSEcCtD
Pomalidomide—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.00147	0.0104	CcSEcCtD
Pomalidomide—Back pain—Riluzole—amyotrophic lateral sclerosis	0.00143	0.0101	CcSEcCtD
Pomalidomide—Muscle spasms—Riluzole—amyotrophic lateral sclerosis	0.00142	0.00999	CcSEcCtD
Pomalidomide—TNF—Amyotrophic lateral sclerosis (ALS)—RAB5A—amyotrophic lateral sclerosis	0.00142	0.0179	CbGpPWpGaD
Pomalidomide—TNF—Amyotrophic lateral sclerosis (ALS)—SLC1A2—amyotrophic lateral sclerosis	0.00142	0.0179	CbGpPWpGaD
Pomalidomide—Thalidomide—PTGS2—amyotrophic lateral sclerosis	0.00138	0.375	CrCbGaD
Pomalidomide—Tremor—Riluzole—amyotrophic lateral sclerosis	0.00138	0.00974	CcSEcCtD
Pomalidomide—Anaemia—Riluzole—amyotrophic lateral sclerosis	0.00136	0.0096	CcSEcCtD
Pomalidomide—Vertigo—Riluzole—amyotrophic lateral sclerosis	0.00132	0.00934	CcSEcCtD
Pomalidomide—Leukopenia—Riluzole—amyotrophic lateral sclerosis	0.00132	0.0093	CcSEcCtD
Pomalidomide—TNF—Amyotrophic lateral sclerosis (ALS)—NEFL—amyotrophic lateral sclerosis	0.00129	0.0164	CbGpPWpGaD
Pomalidomide—Cough—Riluzole—amyotrophic lateral sclerosis	0.00129	0.00907	CcSEcCtD
Pomalidomide—Arthralgia—Riluzole—amyotrophic lateral sclerosis	0.00125	0.00885	CcSEcCtD
Pomalidomide—Anxiety—Riluzole—amyotrophic lateral sclerosis	0.00125	0.00882	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.00125	0.00879	CcSEcCtD
Pomalidomide—TNF—Monoamine Transport—SLC6A1—amyotrophic lateral sclerosis	0.00123	0.0156	CbGpPWpGaD
Pomalidomide—Confusional state—Riluzole—amyotrophic lateral sclerosis	0.00121	0.00855	CcSEcCtD
Pomalidomide—Infection—Riluzole—amyotrophic lateral sclerosis	0.00119	0.00842	CcSEcCtD
Pomalidomide—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.00118	0.00832	CcSEcCtD
Pomalidomide—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.00118	0.0083	CcSEcCtD
Pomalidomide—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.00117	0.00824	CcSEcCtD
Pomalidomide—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.00116	0.0082	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.0011	0.00773	CcSEcCtD
Pomalidomide—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.00109	0.00767	CcSEcCtD
Pomalidomide—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.00107	0.00756	CcSEcCtD
Pomalidomide—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.00105	0.00737	CcSEcCtD
Pomalidomide—TNF—Alzheimers Disease—CASP12—amyotrophic lateral sclerosis	0.00104	0.0132	CbGpPWpGaD
Pomalidomide—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00104	0.00732	CcSEcCtD
Pomalidomide—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.00104	0.00731	CcSEcCtD
Pomalidomide—Constipation—Riluzole—amyotrophic lateral sclerosis	0.00103	0.00725	CcSEcCtD
Pomalidomide—Pain—Riluzole—amyotrophic lateral sclerosis	0.00103	0.00725	CcSEcCtD
Pomalidomide—TNF—Amyotrophic lateral sclerosis (ALS)—CST3—amyotrophic lateral sclerosis	0.00102	0.0129	CbGpPWpGaD
Pomalidomide—CRBN—embryo—amyotrophic lateral sclerosis	0.00101	0.13	CbGeAlD
Pomalidomide—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.000991	0.00699	CcSEcCtD
Pomalidomide—PTGS2—hindlimb—amyotrophic lateral sclerosis	0.000967	0.124	CbGeAlD
Pomalidomide—PTGS2—Spinal Cord Injury—PTPRZ1—amyotrophic lateral sclerosis	0.000956	0.0121	CbGpPWpGaD
Pomalidomide—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.000951	0.0067	CcSEcCtD
Pomalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—RAB5A—amyotrophic lateral sclerosis	0.000935	0.0118	CbGpPWpGaD
Pomalidomide—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—TPK1—amyotrophic lateral sclerosis	0.000924	0.0117	CbGpPWpGaD
Pomalidomide—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.000886	0.00625	CcSEcCtD
Pomalidomide—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.000863	0.00608	CcSEcCtD
Pomalidomide—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.000851	0.006	CcSEcCtD
Pomalidomide—PTGS2—appendage—amyotrophic lateral sclerosis	0.00083	0.106	CbGeAlD
Pomalidomide—TNF—HIV-1 Nef: Negative effector of Fas and TNF-alpha—CASP9—amyotrophic lateral sclerosis	0.000827	0.0105	CbGpPWpGaD
Pomalidomide—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.000823	0.0058	CcSEcCtD
Pomalidomide—CYP1A2—Melatonin metabolism and effects—ECE1—amyotrophic lateral sclerosis	0.000812	0.0103	CbGpPWpGaD
Pomalidomide—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.000795	0.00561	CcSEcCtD
Pomalidomide—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.000765	0.00539	CcSEcCtD
Pomalidomide—Rash—Riluzole—amyotrophic lateral sclerosis	0.000758	0.00535	CcSEcCtD
Pomalidomide—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.000757	0.00534	CcSEcCtD
Pomalidomide—Headache—Riluzole—amyotrophic lateral sclerosis	0.000753	0.00531	CcSEcCtD
Pomalidomide—TNF—Selenium Micronutrient Network—GSR—amyotrophic lateral sclerosis	0.000749	0.00948	CbGpPWpGaD
Pomalidomide—TNF—Amyotrophic lateral sclerosis (ALS)—CASP9—amyotrophic lateral sclerosis	0.000739	0.00936	CbGpPWpGaD
Pomalidomide—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—RARA—amyotrophic lateral sclerosis	0.00073	0.00924	CbGpPWpGaD
Pomalidomide—Nausea—Riluzole—amyotrophic lateral sclerosis	0.000714	0.00504	CcSEcCtD
Pomalidomide—TNF—TNF receptor signaling pathway —SQSTM1—amyotrophic lateral sclerosis	0.00071	0.00899	CbGpPWpGaD
Pomalidomide—TNF—FAS pathway and Stress induction of HSP regulation—CASP9—amyotrophic lateral sclerosis	0.000682	0.00864	CbGpPWpGaD
Pomalidomide—TNF—Amyotrophic lateral sclerosis (ALS)—SOD1—amyotrophic lateral sclerosis	0.000663	0.0084	CbGpPWpGaD
Pomalidomide—CRBN—medulla oblongata—amyotrophic lateral sclerosis	0.000646	0.0828	CbGeAlD
Pomalidomide—TNF—Apoptosis-related network due to altered Notch3 in ovarian cancer—SQSTM1—amyotrophic lateral sclerosis	0.000634	0.00803	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—ECE1—amyotrophic lateral sclerosis	0.000604	0.00765	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—RTN4—amyotrophic lateral sclerosis	0.000603	0.00764	CbGpPWpGaD
Pomalidomide—TNF—Overview of nanoparticle effects—PTGS2—amyotrophic lateral sclerosis	0.000584	0.00739	CbGpPWpGaD
Pomalidomide—TNF—Alzheimers Disease—MAPT—amyotrophic lateral sclerosis	0.000583	0.00739	CbGpPWpGaD
Pomalidomide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—RARA—amyotrophic lateral sclerosis	0.000583	0.00738	CbGpPWpGaD
Pomalidomide—CRBN—spinal cord—amyotrophic lateral sclerosis	0.000576	0.0738	CbGeAlD
Pomalidomide—TNF—Adipogenesis—RARA—amyotrophic lateral sclerosis	0.000569	0.00721	CbGpPWpGaD
Pomalidomide—TNF—Caspase Cascade in Apoptosis—CASP9—amyotrophic lateral sclerosis	0.000534	0.00677	CbGpPWpGaD
Pomalidomide—TNF—Vitamin B12 Metabolism—SOD1—amyotrophic lateral sclerosis	0.000524	0.00664	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—CASP12—amyotrophic lateral sclerosis	0.000513	0.0065	CbGpPWpGaD
Pomalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—ATF1—amyotrophic lateral sclerosis	0.000512	0.00649	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—GFAP—amyotrophic lateral sclerosis	0.000492	0.00623	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—AQP4—amyotrophic lateral sclerosis	0.000486	0.00616	CbGpPWpGaD
Pomalidomide—CRBN—nervous system—amyotrophic lateral sclerosis	0.000486	0.0622	CbGeAlD
Pomalidomide—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—amyotrophic lateral sclerosis	0.000477	0.00605	CbGpPWpGaD
Pomalidomide—CRBN—central nervous system—amyotrophic lateral sclerosis	0.000468	0.0599	CbGeAlD
Pomalidomide—PTGS2—Selenium Micronutrient Network—GSR—amyotrophic lateral sclerosis	0.000463	0.00587	CbGpPWpGaD
Pomalidomide—CRBN—cerebellum—amyotrophic lateral sclerosis	0.000457	0.0585	CbGeAlD
Pomalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—CD40LG—amyotrophic lateral sclerosis	0.000456	0.00578	CbGpPWpGaD
Pomalidomide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—RARA—amyotrophic lateral sclerosis	0.00045	0.0057	CbGpPWpGaD
Pomalidomide—PTGS2—Prostaglandin Synthesis and Regulation—PLA2G4A—amyotrophic lateral sclerosis	0.000444	0.00563	CbGpPWpGaD
Pomalidomide—TNF—Folate Metabolism—SOD1—amyotrophic lateral sclerosis	0.000426	0.0054	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—RARA—amyotrophic lateral sclerosis	0.000418	0.0053	CbGpPWpGaD
Pomalidomide—TNF—Alzheimers Disease—CASP9—amyotrophic lateral sclerosis	0.000411	0.00521	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—CASP9—amyotrophic lateral sclerosis	0.000411	0.00521	CbGpPWpGaD
Pomalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—PLA2G4A—amyotrophic lateral sclerosis	0.000393	0.00497	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—CASP9—amyotrophic lateral sclerosis	0.000392	0.00496	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—SLC1A3—amyotrophic lateral sclerosis	0.000389	0.00493	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—AQP4—amyotrophic lateral sclerosis	0.000389	0.00493	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—CHAT—amyotrophic lateral sclerosis	0.000389	0.00493	CbGpPWpGaD
Pomalidomide—TNF—Vitamin B12 Metabolism—APOE—amyotrophic lateral sclerosis	0.000387	0.0049	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis-related network due to altered Notch3 in ovarian cancer—APOE—amyotrophic lateral sclerosis	0.000375	0.00475	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—RTN4—amyotrophic lateral sclerosis	0.000373	0.00473	CbGpPWpGaD
Pomalidomide—CRBN—brain—amyotrophic lateral sclerosis	0.000371	0.0475	CbGeAlD
Pomalidomide—TNF—TNF alpha Signaling Pathway—CASP9—amyotrophic lateral sclerosis	0.000364	0.00461	CbGpPWpGaD
Pomalidomide—TNF—Matrix Metalloproteinases—MMP9—amyotrophic lateral sclerosis	0.000355	0.0045	CbGpPWpGaD
Pomalidomide—TNF—HIV-1 Nef: Negative effector of Fas and TNF-alpha—CASP3—amyotrophic lateral sclerosis	0.000348	0.00441	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—MAPT—amyotrophic lateral sclerosis	0.00034	0.00431	CbGpPWpGaD
Pomalidomide—TNF—Selenium Micronutrient Network—SOD1—amyotrophic lateral sclerosis	0.000339	0.00429	CbGpPWpGaD
Pomalidomide—TNF—amb2 Integrin signaling—MMP9—amyotrophic lateral sclerosis	0.000337	0.00427	CbGpPWpGaD
Pomalidomide—TNF—Ceramide signaling pathway—IGF1—amyotrophic lateral sclerosis	0.000335	0.00425	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—CD40LG—amyotrophic lateral sclerosis	0.000331	0.00419	CbGpPWpGaD
Pomalidomide—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—amyotrophic lateral sclerosis	0.000326	0.00413	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—MAPT—amyotrophic lateral sclerosis	0.000319	0.00404	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CASP12—amyotrophic lateral sclerosis	0.000317	0.00402	CbGpPWpGaD
Pomalidomide—TNF—Amyotrophic lateral sclerosis (ALS)—CASP3—amyotrophic lateral sclerosis	0.000311	0.00394	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—GFAP—amyotrophic lateral sclerosis	0.000304	0.00385	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—AQP4—amyotrophic lateral sclerosis	0.000301	0.00381	CbGpPWpGaD
Pomalidomide—TNF—Cardiac Hypertrophic Response—IGF1—amyotrophic lateral sclerosis	0.000301	0.00381	CbGpPWpGaD
Pomalidomide—PTGS2—Arachidonic acid metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000295	0.00374	CbGpPWpGaD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—amyotrophic lateral sclerosis	0.000295	0.00374	CbGpPWpGaD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—SQSTM1—amyotrophic lateral sclerosis	0.000293	0.00371	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—C3—amyotrophic lateral sclerosis	0.000293	0.00371	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—MAPT—amyotrophic lateral sclerosis	0.000288	0.00365	CbGpPWpGaD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor—PTGS2—amyotrophic lateral sclerosis	0.000288	0.00364	CbGpPWpGaD
Pomalidomide—TNF—FAS pathway and Stress induction of HSP regulation—CASP3—amyotrophic lateral sclerosis	0.000287	0.00364	CbGpPWpGaD
Pomalidomide—TNF—TWEAK Signaling Pathway—CASP3—amyotrophic lateral sclerosis	0.000287	0.00364	CbGpPWpGaD
Pomalidomide—PTGS2—S1P1 pathway—VEGFA—amyotrophic lateral sclerosis	0.000284	0.0036	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—CST3—amyotrophic lateral sclerosis	0.000279	0.00354	CbGpPWpGaD
Pomalidomide—PTGS2—embryo—amyotrophic lateral sclerosis	0.000275	0.0353	CbGeAlD
Pomalidomide—TNF—Alzheimers Disease—APOE—amyotrophic lateral sclerosis	0.000272	0.00345	CbGpPWpGaD
Pomalidomide—TNF—TWEAK Signaling Pathway—MMP9—amyotrophic lateral sclerosis	0.000271	0.00344	CbGpPWpGaD
Pomalidomide—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PTGS2—amyotrophic lateral sclerosis	0.000269	0.00341	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—IGFBP3—amyotrophic lateral sclerosis	0.000263	0.00333	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—RARA—amyotrophic lateral sclerosis	0.000259	0.00328	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—BDNF—amyotrophic lateral sclerosis	0.000252	0.00319	CbGpPWpGaD
Pomalidomide—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CASP3—amyotrophic lateral sclerosis	0.00025	0.00316	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—CASP9—amyotrophic lateral sclerosis	0.00024	0.00304	CbGpPWpGaD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor—VEGFA—amyotrophic lateral sclerosis	0.000227	0.00287	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CASP12—amyotrophic lateral sclerosis	0.000225	0.00285	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—CASP9—amyotrophic lateral sclerosis	0.000225	0.00285	CbGpPWpGaD
Pomalidomide—TNF—Caspase Cascade in Apoptosis—CASP3—amyotrophic lateral sclerosis	0.000225	0.00285	CbGpPWpGaD
Pomalidomide—TNF—MicroRNAs in cardiomyocyte hypertrophy—IGF1—amyotrophic lateral sclerosis	0.000214	0.00271	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—IGF1—amyotrophic lateral sclerosis	0.000214	0.00271	CbGpPWpGaD
Pomalidomide—CYP1A2—Melatonin metabolism and effects—APOE—amyotrophic lateral sclerosis	0.000213	0.00269	CbGpPWpGaD
Pomalidomide—PTGS2—Selenium Micronutrient Network—SOD1—amyotrophic lateral sclerosis	0.000209	0.00265	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	0.000206	0.00261	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—CASP9—amyotrophic lateral sclerosis	0.000203	0.00257	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—BDNF—amyotrophic lateral sclerosis	0.000201	0.00255	CbGpPWpGaD
Pomalidomide—TNF—Amyotrophic lateral sclerosis (ALS)—TP53—amyotrophic lateral sclerosis	0.000199	0.00253	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—BDNF—amyotrophic lateral sclerosis	0.00019	0.0024	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	0.000188	0.00238	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—RARA—amyotrophic lateral sclerosis	0.000183	0.00232	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—CASP9—amyotrophic lateral sclerosis	0.00018	0.00228	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MAPT—amyotrophic lateral sclerosis	0.000178	0.00225	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—PFN1—amyotrophic lateral sclerosis	0.000176	0.00223	CbGpPWpGaD
Pomalidomide—PTGS2—medulla oblongata—amyotrophic lateral sclerosis	0.000176	0.0225	CbGeAlD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	0.000175	0.00222	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—CASP3—amyotrophic lateral sclerosis	0.000173	0.00219	CbGpPWpGaD
Pomalidomide—TNF—Alzheimers Disease—CASP3—amyotrophic lateral sclerosis	0.000173	0.00219	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CST3—amyotrophic lateral sclerosis	0.000173	0.00219	CbGpPWpGaD
Pomalidomide—TNF—Selenium Micronutrient Network—PTGS2—amyotrophic lateral sclerosis	0.000171	0.00217	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—BDNF—amyotrophic lateral sclerosis	0.000171	0.00217	CbGpPWpGaD
Pomalidomide—ABCB1—embryo—amyotrophic lateral sclerosis	0.00017	0.0218	CbGeAlD
Pomalidomide—CYP1A2—Arachidonic acid metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000167	0.00212	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—CASP3—amyotrophic lateral sclerosis	0.000165	0.00209	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	0.000164	0.00208	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—PLA2G4A—amyotrophic lateral sclerosis	0.000163	0.00207	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—IGFBP3—amyotrophic lateral sclerosis	0.000163	0.00206	CbGpPWpGaD
Pomalidomide—PTGS2—spinal cord—amyotrophic lateral sclerosis	0.000157	0.0201	CbGeAlD
Pomalidomide—PTGS2—Spinal Cord Injury—BDNF—amyotrophic lateral sclerosis	0.000156	0.00197	CbGpPWpGaD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CASP3—amyotrophic lateral sclerosis	0.000154	0.00196	CbGpPWpGaD
Pomalidomide—TNF—TNF alpha Signaling Pathway—CASP3—amyotrophic lateral sclerosis	0.000153	0.00194	CbGpPWpGaD
Pomalidomide—CYP1A2—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.000151	0.00192	CbGpPWpGaD
Pomalidomide—TNF—Adipogenesis—IGF1—amyotrophic lateral sclerosis	0.000151	0.00191	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—VEGFA—amyotrophic lateral sclerosis	0.000147	0.00186	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—CD40LG—amyotrophic lateral sclerosis	0.000145	0.00184	CbGpPWpGaD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—amyotrophic lateral sclerosis	0.00014	0.00178	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—PTGS2—amyotrophic lateral sclerosis	0.000135	0.00172	CbGpPWpGaD
Pomalidomide—PTGS2—nervous system—amyotrophic lateral sclerosis	0.000132	0.0169	CbGeAlD
Pomalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—amyotrophic lateral sclerosis	0.000132	0.00167	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—C3—amyotrophic lateral sclerosis	0.000128	0.00162	CbGpPWpGaD
Pomalidomide—TNF—Folate Metabolism—TP53—amyotrophic lateral sclerosis	0.000128	0.00162	CbGpPWpGaD
Pomalidomide—PTGS2—central nervous system—amyotrophic lateral sclerosis	0.000127	0.0163	CbGeAlD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MAPT—amyotrophic lateral sclerosis	0.000126	0.0016	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—CASP3—amyotrophic lateral sclerosis	0.000126	0.00159	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CASP9—amyotrophic lateral sclerosis	0.000126	0.00159	CbGpPWpGaD
Pomalidomide—PTGS2—cerebellum—amyotrophic lateral sclerosis	0.000124	0.0159	CbGeAlD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CST3—amyotrophic lateral sclerosis	0.000122	0.00155	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—MMP9—amyotrophic lateral sclerosis	0.000119	0.0015	CbGpPWpGaD
Pomalidomide—CYP3A4—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.000117	0.00148	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	0.000116	0.00147	CbGpPWpGaD
Pomalidomide—CYP1A2—Phase II conjugation—GSTP1—amyotrophic lateral sclerosis	0.000116	0.00147	CbGpPWpGaD
Pomalidomide—CYP3A4—nervous system—amyotrophic lateral sclerosis	0.000116	0.0148	CbGeAlD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—IGFBP3—amyotrophic lateral sclerosis	0.000115	0.00146	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	0.000113	0.00143	CbGpPWpGaD
Pomalidomide—CYP3A4—central nervous system—amyotrophic lateral sclerosis	0.000111	0.0142	CbGeAlD
Pomalidomide—TNF—Alzheimers Disease—TP53—amyotrophic lateral sclerosis	0.000111	0.00141	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	0.000111	0.00141	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—TPK1—amyotrophic lateral sclerosis	0.000109	0.00139	CbGpPWpGaD
Pomalidomide—ABCB1—medulla oblongata—amyotrophic lateral sclerosis	0.000109	0.0139	CbGeAlD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	0.000106	0.00135	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—BDNF—amyotrophic lateral sclerosis	0.000106	0.00134	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—TP53—amyotrophic lateral sclerosis	0.000106	0.00134	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	0.000105	0.00133	CbGpPWpGaD
Pomalidomide—PTGS2—brain—amyotrophic lateral sclerosis	0.000101	0.0129	CbGeAlD
Pomalidomide—TNF—Apoptosis—CASP3—amyotrophic lateral sclerosis	0.000101	0.00128	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PLA2G4A—amyotrophic lateral sclerosis	0.000101	0.00128	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—amyotrophic lateral sclerosis	0.000101	0.00128	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—CASP3—amyotrophic lateral sclerosis	0.000101	0.00127	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	9.9e-05	0.00125	CbGpPWpGaD
Pomalidomide—ABCB1—spinal cord—amyotrophic lateral sclerosis	9.71e-05	0.0124	CbGeAlD
Pomalidomide—TNF—MAPK Signaling Pathway—CASP3—amyotrophic lateral sclerosis	9.47e-05	0.0012	CbGpPWpGaD
Pomalidomide—CYP1A2—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	9.42e-05	0.00119	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	9.31e-05	0.00118	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	9.21e-05	0.00117	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—TPK1—amyotrophic lateral sclerosis	9.16e-05	0.00116	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—VAPB—amyotrophic lateral sclerosis	9.16e-05	0.00116	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CASP9—amyotrophic lateral sclerosis	8.9e-05	0.00113	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—VTA1—amyotrophic lateral sclerosis	8.75e-05	0.00111	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	8.55e-05	0.00108	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	8.54e-05	0.00108	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—VEGFA—amyotrophic lateral sclerosis	8.53e-05	0.00108	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—VAPA—amyotrophic lateral sclerosis	8.38e-05	0.00106	CbGpPWpGaD
Pomalidomide—ABCB1—nervous system—amyotrophic lateral sclerosis	8.18e-05	0.0105	CbGeAlD
Pomalidomide—TNF—Spinal Cord Injury—TP53—amyotrophic lateral sclerosis	8.06e-05	0.00102	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—amyotrophic lateral sclerosis	7.93e-05	0.001	CbGpPWpGaD
Pomalidomide—ABCB1—central nervous system—amyotrophic lateral sclerosis	7.88e-05	0.0101	CbGeAlD
Pomalidomide—PTGS2—Metabolism—SACM1L—amyotrophic lateral sclerosis	7.79e-05	0.000987	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—CASP3—amyotrophic lateral sclerosis	7.77e-05	0.000985	CbGpPWpGaD
Pomalidomide—ABCB1—cerebellum—amyotrophic lateral sclerosis	7.7e-05	0.00986	CbGeAlD
Pomalidomide—ABCB1—Allograft Rejection—CASP3—amyotrophic lateral sclerosis	7.6e-05	0.000962	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—amyotrophic lateral sclerosis	7.5e-05	0.00095	CbGpPWpGaD
Pomalidomide—ABCB1—HIF-1-alpha transcription factor network—VEGFA—amyotrophic lateral sclerosis	7.44e-05	0.000943	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—MMP9—amyotrophic lateral sclerosis	7.35e-05	0.00093	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—FIG4—amyotrophic lateral sclerosis	7.32e-05	0.000928	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	7.26e-05	0.000919	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PLA2G4A—amyotrophic lateral sclerosis	7.16e-05	0.000907	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	6.87e-05	0.00087	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	6.77e-05	0.000858	CbGpPWpGaD
Pomalidomide—CYP1A2—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	6.77e-05	0.000857	CbGpPWpGaD
Pomalidomide—CYP1A2—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	6.67e-05	0.000845	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CHMP2B—amyotrophic lateral sclerosis	6.63e-05	0.00084	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—DAO—amyotrophic lateral sclerosis	6.62e-05	0.000839	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—VAPB—amyotrophic lateral sclerosis	6.49e-05	0.000823	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—TPK1—amyotrophic lateral sclerosis	6.49e-05	0.000823	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—TP53—amyotrophic lateral sclerosis	6.48e-05	0.000821	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—VEGFA—amyotrophic lateral sclerosis	6.45e-05	0.000816	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	6.38e-05	0.000808	CbGpPWpGaD
Pomalidomide—ABCB1—brain—amyotrophic lateral sclerosis	6.25e-05	0.00801	CbGeAlD
Pomalidomide—TNF—MAPK Signaling Pathway—TP53—amyotrophic lateral sclerosis	6.07e-05	0.000769	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—PLB1—amyotrophic lateral sclerosis	5.99e-05	0.000759	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—VAPA—amyotrophic lateral sclerosis	5.94e-05	0.000752	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	5.76e-05	0.000729	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	5.76e-05	0.000729	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—SACM1L—amyotrophic lateral sclerosis	5.52e-05	0.0007	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	5.48e-05	0.000694	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—VCP—amyotrophic lateral sclerosis	5.34e-05	0.000677	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	5.29e-05	0.00067	CbGpPWpGaD
Pomalidomide—CYP3A4—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	5.22e-05	0.000661	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—FIG4—amyotrophic lateral sclerosis	5.19e-05	0.000658	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—VAPB—amyotrophic lateral sclerosis	5.18e-05	0.000657	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—TPK1—amyotrophic lateral sclerosis	5.18e-05	0.000657	CbGpPWpGaD
Pomalidomide—CYP3A4—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	5.15e-05	0.000652	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	5.13e-05	0.00065	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PLB1—amyotrophic lateral sclerosis	5.02e-05	0.000636	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—TP53—amyotrophic lateral sclerosis	4.98e-05	0.000631	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	4.87e-05	0.000617	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	4.83e-05	0.000612	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—VAPA—amyotrophic lateral sclerosis	4.74e-05	0.000601	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—DAO—amyotrophic lateral sclerosis	4.7e-05	0.000595	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—GSR—amyotrophic lateral sclerosis	4.63e-05	0.000587	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	4.49e-05	0.000568	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—SACM1L—amyotrophic lateral sclerosis	4.41e-05	0.000558	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	4.22e-05	0.000534	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—FIG4—amyotrophic lateral sclerosis	4.15e-05	0.000525	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	4.04e-05	0.000511	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—VAPB—amyotrophic lateral sclerosis	4e-05	0.000507	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—TPK1—amyotrophic lateral sclerosis	4e-05	0.000507	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CST3—amyotrophic lateral sclerosis	3.83e-05	0.000486	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—CHAT—amyotrophic lateral sclerosis	3.8e-05	0.000482	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—MMP9—amyotrophic lateral sclerosis	3.78e-05	0.000479	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—DAO—amyotrophic lateral sclerosis	3.75e-05	0.000475	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	3.75e-05	0.000475	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—VAPA—amyotrophic lateral sclerosis	3.66e-05	0.000464	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PLB1—amyotrophic lateral sclerosis	3.56e-05	0.000451	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	3.47e-05	0.00044	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—SACM1L—amyotrophic lateral sclerosis	3.4e-05	0.000431	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	3.39e-05	0.00043	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	3.39e-05	0.000429	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GSR—amyotrophic lateral sclerosis	3.28e-05	0.000416	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—FIG4—amyotrophic lateral sclerosis	3.2e-05	0.000405	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	3.18e-05	0.000403	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—DAO—amyotrophic lateral sclerosis	2.89e-05	0.000366	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PLB1—amyotrophic lateral sclerosis	2.84e-05	0.00036	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CASP9—amyotrophic lateral sclerosis	2.79e-05	0.000353	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CHAT—amyotrophic lateral sclerosis	2.7e-05	0.000342	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GSR—amyotrophic lateral sclerosis	2.62e-05	0.000332	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	2.4e-05	0.000304	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	2.39e-05	0.000302	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—ERBB4—amyotrophic lateral sclerosis	2.39e-05	0.000302	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PLB1—amyotrophic lateral sclerosis	2.19e-05	0.000278	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CHAT—amyotrophic lateral sclerosis	2.15e-05	0.000273	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.04e-05	0.000259	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GSR—amyotrophic lateral sclerosis	2.02e-05	0.000256	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.96e-05	0.000249	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.88e-05	0.000238	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—APOE—amyotrophic lateral sclerosis	1.85e-05	0.000234	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CHAT—amyotrophic lateral sclerosis	1.66e-05	0.00021	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—APOE—amyotrophic lateral sclerosis	1.55e-05	0.000196	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.45e-05	0.000184	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	1.35e-05	0.000171	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.33e-05	0.000169	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.16e-05	0.000147	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—APOE—amyotrophic lateral sclerosis	1.1e-05	0.000139	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.06e-05	0.000135	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GSTP1—amyotrophic lateral sclerosis	8.93e-06	0.000113	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—APOE—amyotrophic lateral sclerosis	8.75e-06	0.000111	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	8.21e-06	0.000104	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PTGS2—amyotrophic lateral sclerosis	7.51e-06	9.51e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—APOE—amyotrophic lateral sclerosis	6.75e-06	8.55e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PTGS2—amyotrophic lateral sclerosis	5.99e-06	7.59e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PTGS2—amyotrophic lateral sclerosis	4.63e-06	5.86e-05	CbGpPWpGaD
